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We would like to thank Dr Westerweel and colleagues 
for their interest regarding our paper [1]. The purpose of 
our study was to report the characteristics and clinical out-
come of French patients living in Paris’ area and victims of 
decompression sickness (DCS). 
We also pointed out a “French paradox”: in fact aspirin is 
widely recommended in France in DCS treatment (whatever 
the symptomatology and as soon as possible) according to 
a clear theoretical rationale, but on the opposite, most of 
other countries (USA, UK, North of Europe, Asia) do not use 
this antiplatelet agent [2].
Indeed, it’s still unclear whether there is a benefit to 
give aspirin to injured divers or not. International literature 
is scarce on this subject and only provides few experimental 
data, rather as preventive treatment. But to our knowledge, 
no data has been published regarding the role of aspirin as 
therapeutic agent after DCS, especially in humans [2, 3].
Nevertheless, Dr Westerweel is right to ask for poten-
tially bleeding complications of such antiplatelet agents 
administration: aspirin today, Prasugrel or Ticagrelor tomor-
row. While 38% of patients received aspirin on the site of 
accident, any of others received aspirin once admitted to 
our hyperbaric facility. The comparison between 2 groups 
of divers (aspirin vs. no aspirin) had not been performed. 
Nevertheless, we found no symptomatic bleeding compli-
cation in divers who received aspirin before hyperbaric 
facility admission, but our study lacks sufficient power to 
adequately evaluate the safety of aspirin administration. 
However, we agree with Dr Westerweel comments that in a 
trial evaluating the benefit of aspirin in this indication, eva-
luation of its safety regarding bleeding would be required. 
Finally, we totally agree with the fact that a randomised 
clinical trial (RCT) should be realised to complete the experi-
mental data published by Pontier and his team from Toulon, 
France [4]. However, such a RCT will be difficult to realise 
in France, because most diving accidents occur along the 
Atlantic and Mediterranean coasts, where aspirin is widely 
used on the site of the accident or diving boats. Thus, 
inclusion of aspirin-free victims of DCS will not be so easy.
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